LSP 7 Cooperative UA

CIK: 0001876264

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EVMN

Evommune, Inc.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (3 total)

EVMN
Evommune, Inc.
Feb 17, 2026
Award(A)
Indirect
358.7K shares at avg. $27.88$10.0M
EVMN
Evommune, Inc.
Nov 7, 2025
Conversion(C)
Direct
3.4M shares-
EVMN
Evommune, Inc.
Nov 7, 2025
Purchase(P)
Direct
1.6M shares at avg. $16.00$25.0M

		Type	Shares	Price		Ownership
Feb 17, 2026	EVMN Evommune, Inc.	Award(A)	358,680	$27.88	$9,999,998	Indirect
Nov 7, 2025	EVMN Evommune, Inc.	Conversion(C)	3,367,133	-	-	Direct
Nov 7, 2025	EVMN Evommune, Inc.	Purchase(P)	1,562,500	$16.00	$25,000,000	Direct

1-3 of 3 transactions

About LSP 7 Cooperative UA

LSP 7 Cooperative UA (SEC CIK 0001876264) files insider reports with the SEC as Director of Evommune, Inc. (EVMN).

Signal8 holds 3 ownership filings by LSP 7 Cooperative UA (1 Form 3, 2 Form 4), filed between Nov 5, 2025 and Feb 19, 2026. Those filings report 3 transactions, from Nov 7, 2025 to Feb 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LSP 7 Cooperative UA's filings is in AMSTERDAM, P7.

Recent filings by LSP 7 Cooperative UA

Feb 17, 2026: Grant or award of EVMN shares (Form 4, code A).
Nov 7, 2025: Conversion of EVMN shares (Form 4, code C).
Nov 7, 2025: Open-market purchase of EVMN shares (Form 4, code P).

Other insiders filing for Evommune, Inc. (EVMN)

Pena Luis C., President & CEO
Carver Kyle, Chief Financial Officer
KIRSCH ARTHUR S, Director
Drew Janice Suzann, Chief of Dev. Operations
Patel Jeegar Pravinkumar, Chief Scientific Officer
MCGRAW BENJAMIN F III, Director

How to read Form 4 transaction codes